CryoPort, Inc. · NASDAQ:CYRX

CryoPort — Q3 2026 Earnings Presentation

18 slides from CryoPort's earnings presentation, Nov 5, 2026

  1. Slide 1: Q3 2026 Earnings Deck

    Q3 2026 Earnings Deck November 5th, 2026

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Forward-Looking Statements Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking stateme

  3. Slide 3: Cryoport – Trusted Partner to Life Sciences Companies

    Cryoport – Trusted Partner to Life Sciences Companies Life sciences company focused on providing mission critical, proprietary temperature-controlled supply chain solutions Capabilities include core competencies to ship, store and deliver biologics in a cryogenic or temperature-controlled state such

  4. Slide 4: The Cryoport Platform: Services & Products

    The Cryoport Platform: Services & Products Core services and products supporting the management of critical biomaterials Life Sciences Services 57% Life Sciences Products 43% +18% YoY +8% YoY Q3 FY2026 Q3 FY2026 BioLogistics IntegriCell® BioServices BioStorage Cryogenic Systems (Launched in 2024) (L

  5. Slide 5: Cryoport Snapshot – By the Numbers

    Cryoport Snapshot – By the Numbers Leading integrated platform ensuring the integrity of critical biomaterials across the life sciences value chain $50.2M $197M-$199M 47.5% $1.1M +14% Organic Growth +12%* Organic Growth -75bps YoY +$1.8M FY2026E Q3 FY2026 Revenue Updated Revenue Guidance from Q3 FY2

  6. Slide 6: Revenue from Supporting Commercial Cell and Gene Therapies

    Revenue from Supporting Commercial Cell and Gene Therapies Q1 2025 through Q3 2026 © 2026 CRYOPORT, INC. 6

  7. Slide 7: Q3 2026 Revenue Drivers

    Q3 2026 Revenue Drivers Strong growth across the platform of products and services offerings +18% Cell & Gene Therapy Revenue Life Sciences Services Revenue +20% +15% Commercial +8% Clinical Trial Cell & Gene Cell & Gene Therapy Therapy Life Sciences +25% Revenue Products BioServices & Revenue Reven

  8. Slide 8: Patients First: Supporting the Therapies of Tomorrow

    Patients First: Supporting the Therapies of Tomorrow Clinical Trials Supported, by Trial Phase Phase I Phase II Phase III Quarterly Trial count as of the end of the respective periods © 2026 CRYOPORT, INC. 8

  9. Slide 9: Supporting Commercial Cell and Gene Therapies Globally

    Supporting 23 Commercial Cell and Gene Therapies Globally アクーゴ AKUUGO® © 2026 CRYOPORT, INC. 9

  10. Slide 10: Cryoport, Inc. Global Locations

    Cryoport, Inc. Global Locations Amsterdam, NL Global Logistics Center Morris Plains, NJ Global Supply Chain Center Stevenage, UK Tokyo, Japan Supply Chain Hub Global Logistics Center New Prague, MN Darmstadt, DE Manufacturing Facility Tec4med Lifescience Chengdu, China Manufacturing Facility Nashvil

  11. Slide 11: Driving Bottom-Line Improvement

    Driving Bottom-Line Improvement 47.5% $1.1M $393.1M Gross Margin Adjusted EBITDA Cash and from Continuing from Continuing Short-Term Operations Operations Investment © 2026 CRYOPORT, INC. 11

  12. Slide 12: Global Cell and Gene Therapy Market

    Global Cell and Gene Therapy Market $143.6B 2034E $16.5B 2026 5.04 6.42 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2021–2034 ($ Billion) www.fortunebusinessinsights.com © 2026 CRYOPORT, INC. 12

  13. Slide 13: 2026 CGT Investment Significantly Outpacing 2025

    2026 CGT Investment Significantly Outpacing 2025 $20 $11.3B+ $15.2 Total sector financings $15 through Q3 2026* $11.7 $11.3 $11.2 $10 +43% $5 $7.9B Q1–Q3 2025 YoY increase from Q1 – Q3 2025 $- FY2023 FY2024 FY2025 Q1 - Q3 2026 Reporting Period $ Billion *Q3 2026 Data is Preliminary Source: Alliance

  14. Slide 14: Q3-2026 Clinical Trial Support

    Q3-2026 Clinical Trial Support Trial count as of the end of the respective periods © 2026 CRYOPORT, INC. 14

  15. Slide 15: Q3-2026 and 9M-2026 Revenue

    Q3-2026 and 9M-2026 Revenue © 2026 CRYOPORT, INC. 15

  16. Slide 16: Condensed Consolidated Statements of Operations

    Cryopor., Ine. and Subsidiaries Condensed Consolidated Statements of Operations ‘Three Months Ended ‘Nine Months Ended ‘September 30, September 20, (unaudited) (unaudited) [in thousands, excent share and pershare data) 2026 2025 2026 E 24758 $83,031 § 19,575, 63,558 Life Sclences Services revenue $

  17. Slide 17: Q3-2026 and 9M-2026 Balance Sheets

    Q3-2026 and 9M-2026 Balance Sheets © 2026 CRYOPORT, INC. 17

  18. Slide 18: Q3-2026 and 9M-2026 Adjusted EBITDA

    Q3-2026 and 9M-2026 Adjusted EBITDA © 2026 CRYOPORT, INC. 18

Cryoport — Q3 2026 Earnings Presentation on 6ix